Cell and Gene Therapy CROs Market, 2021-2030
Roots Analysis has just released the 2nd edition of their study on 'Cell and Gene Therapy CROs Market, 2021-2030'.
The development of cell and gene therapies is not only complex and challenging, but also subject to heavy regulatory scrutiny. Outsourcing is, therefore, a preferred operational model in this field, with innovator companies relying heavily on specialty contract service providers to handle various aspects of their product development and manufacturing operations. Contract research organizations (CROs) that claim to have the necessary capabilities to facilitate cell and gene therapy-related R&D, usually have extensive experience and are well-aware of the nuances of ATMP design and development. Given the rising trend of outsourcing in the healthcare industry and the ongoing efforts of service providers to further improve/expand their respective offerings, they believe the cell and gene therapy CRO market is likely to evolve at a steady pace, till 2030.
Find more information, here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
